Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant
Kevin K. Ariën, Leo Heyndríckx, Johan Míchiels, Katleen Vereecken, Kurt Van Lent, Sandra Coppens, Betty Willems, Pieter Pannus, Geert A. Martens, Marjan Van Esbroeck, Maria E. Goossens, Arnaud Marchant, Koen Bartholomeeusen, Isabelle Desombere
Abstract
We report the levels of neutralising antibodies against Wuhan, Delta and Omicron variants in unimmunized infected (group 1), immunised and boosted (group 2) and infected immunised and boosted (group 3) adult individuals. Our observations support the rapid administration of a booster vaccine dose to prevent infection and disease caused by Omicron.
Topics & Concepts
VirologyAntibodyMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Booster (rocketry)Coronavirus disease 2019 (COVID-19)DiseaseImmunologyInfectious disease (medical specialty)Internal medicinePhysicsAstronomySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesBacillus and Francisella bacterial research